Baxter International Inc. has entered an exclusive 20-year partnership with Hemobrás (Empresa Brasileira de Hemoderivados e Biotechnologia) to provide hemophilia patients in Brazil greater access to recombinant factor VIII (rFVIII) therapy for the treatment of hemophilia A. “Our unique collaboration with Hemobrás is a demonstration of Baxter’s leadership in hemophilia, reflects our expertise and commitment to the community, and positions us as an attractive partner that can make a significant i...